TRVN:OTCMKTS
Trevena Inc
$0.066
0.00%
(0.00) 1 日
10月12日, 14:57:26 GMT-4 · USD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoTRVN の上位の分析情報を生成しています...
時価総額
5.70万
平均出来高
210.00
取引量
16.00
52 週高値
$1.50
52 週安値
$0.00
ベータ版
1.07
発行済株式数
86.40万
従業員数
23
時価総額
5.70万
平均出来高
210.00
取引量
16.00
52 週高値
$1.50
52 週安値
$0.00
ベータ版
1.07
発行済株式数
86.40万
従業員数
23
ニュース記事
情報源: ウェブソース、ニュース パートナー
ad-hoc-news.de
·
1 日前
MarketBeat estimates results for Trevena stock
プロフィール
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Trevena Inc について